A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment

NCT03983161 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers
Hepatic Impairment

Interventions

DRUG: Fedratinib

Sponsor

Celgene

Collaborators

[object Object]